Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff P Sharman

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic LeukemiaJeff P Sharman, Steven E Coutre, Richard R Furman, et al.
Leukemia|April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignanciesRichard R Furman, John C Byrd, Roger G Owen, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
The Lancet. Haematology|November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm studyMazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
Lancet (London, England)|April 20, 2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trialJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Blood|January 10, 2023
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trialYuqin Song, Hervé Tilly, Shinya Rai, et al.
The New England Journal of Medicine|January 24, 2014
Idelalisib and rituximab in relapsed chronic lymphocytic leukemiaRichard R Furman, Jeff P Sharman, Steven E Coutre, et al.
Blood|April 8, 2025
Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TNJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic LeukemiaJeff P Sharman, Steven E Coutre, Richard R Furman, et al.
Leukemia|April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignanciesRichard R Furman, John C Byrd, Roger G Owen, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
The Lancet. Haematology|November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm studyMazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
Lancet (London, England)|April 20, 2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trialJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Blood|January 10, 2023
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trialYuqin Song, Hervé Tilly, Shinya Rai, et al.
The New England Journal of Medicine|January 24, 2014
Idelalisib and rituximab in relapsed chronic lymphocytic leukemiaRichard R Furman, Jeff P Sharman, Steven E Coutre, et al.
Blood|April 8, 2025
Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TNJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Pageof 8